Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Revenue
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
|
Revenue
zł50.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Revenue
zł14.8m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Revenue
zł15.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
19%
|
CAGR 10-Years
26%
|
|
|
G
|
Genomed SA
WSE:GEN
|
Revenue
zł23m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioton SA
WSE:BIO
|
Revenue
zł295.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-3%
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Revenue
zł53.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 223 full-time employees. The company went IPO on 2011-07-29.
See Also
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Revenue?
Revenue
50.4m
PLN
Based on the financial report for Dec 31, 2022, Biomed Lublin Wytwornia Surowic i Szczepionek SA's Revenue amounts to 50.4m PLN.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Revenue growth rate?
Revenue CAGR 5Y
10%
Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Biomed Lublin Wytwornia Surowic i Szczepionek SA have been 9% over the past three years , 10% over the past five years .